Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.53
-$0.01-1.13%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.78M | 7.90M | 8.49M | 8.27M | 7.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.48M | 16.93M | 20.20M | 22.93M | 27.36M |
| Operating Income | -13.48M | -16.93M | -20.20M | -22.93M | -27.36M |
| Income Before Tax | -13.01M | -16.61M | -19.85M | -22.74M | -27.09M |
| Income Tax Expenses | 11.60K | 17.00K | 18.90K | 20.70K | 17.90K |
| Earnings from Continuing Operations | -13.02 | -16.63 | -19.86 | -22.76 | -27.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.02M | -16.63M | -19.86M | -22.76M | -27.11M |
| EBIT | -13.48M | -16.93M | -20.20M | -22.93M | -27.36M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.31 | -4.53 | -6.68 | -9.19 | -13.03 |
| Normalized Basic EPS | -1.44 | -2.83 | -4.17 | -5.74 | -8.14 |
| EPS Diluted | -2.31 | -4.53 | -6.68 | -9.19 | -13.03 |
| Normalized Diluted EPS | -1.44 | -2.83 | -4.17 | -5.74 | -8.14 |
| Average Basic Shares Outstanding | 29.81M | 19.12M | 14.56M | 10.66M | 8.71M |
| Average Diluted Shares Outstanding | 29.81M | 19.12M | 14.56M | 10.66M | 8.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |